Zynex (NASDAQ:ZYXI – Get Free Report) posted its earnings results on Thursday. The company reported $0.04 earnings per share for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04), Briefing.com reports. Zynex had a return on equity of 13.14% and a net margin of 3.12%. The company had revenue of $49.88 million for the quarter, compared to the consensus estimate of $51.99 million. During the same period in the previous year, the firm posted $0.09 EPS. The business’s quarterly revenue was up 11.0% compared to the same quarter last year.
Zynex Trading Down 12.4 %
NASDAQ:ZYXI opened at $8.93 on Friday. Zynex has a 52 week low of $6.88 and a 52 week high of $13.77. The firm’s fifty day moving average is $9.55 and its 200-day moving average is $11.06. The firm has a market cap of $283.71 million, a P/E ratio of 38.83 and a beta of 0.53. The company has a debt-to-equity ratio of 1.76, a quick ratio of 2.87 and a current ratio of 3.58.
Analyst Ratings Changes
A number of analysts have recently commented on ZYXI shares. Royal Bank of Canada cut their price target on Zynex from $15.00 to $12.00 and set an “outperform” rating on the stock in a research note on Friday. HC Wainwright reduced their target price on shares of Zynex from $21.00 to $16.00 and set a “buy” rating on the stock in a report on Friday.
Zynex Company Profile
Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.
Featured Stories
- Five stocks we like better than Zynex
- What Investors Need to Know About Upcoming IPOs
- Is Crypto Cool Again? What Stocks You Should Be Watching
- The 3 Best Blue-Chip Stocks to Buy Now
- Why Call Options Volume for These 2 Stocks Spiked Together
- High Dividend REITs: Are They an Ideal Way to Diversify?
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.
